Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study.

BACKGROUND: Laparoscopic surgery, fast-track perioperative treatment and XELOX chemotherapy are effective strategies for shortening the duration of hospital stay for cancer patients. This trial aimed to clarify the safety and efficacy of the fast-track multidisciplinary treatment (FTMDT) model compared to conventional surgery combined with chemotherapy in Chinese colorectal cancer patients. METHODS: This trial was a prospective randomized controlled study with a 2 × 2 balanced factorial design and was conducted at six hospitals. Patients in group 1 (FTMDT) received fast-track perioperative treatment and XELOX adjuvant chemotherapy. Patients in group 2 (conventional treatment) received conventional perioperative treatment and mFOLFOX6 adjuvant chemotherapy. Subgroups 1a and 2a had laparoscopic surgery and subgroups 1b and 2b had open surgery. The primary endpoint was total length of hospital stay during treatment. RESULTS: A total of 374 patients were randomly assigned to the four subgroups, and 342 patients were finally analyzed, including 87 patients in subgroup 1a, 85 in subgroup 1b, 86 in subgroup 2a, and 84 in subgroup 2b. The total hospital stay of group 1 was shorter than that of group 2 [13 days, (IQR, 11-17 days) vs. 23.5 days (IQR, 15-42 days), P = 0.0001]. Compared to group 2, group 1 had lower surgical costs, fewer in-hospital complications and faster recovery (all P < 0.05). Subgroup 1a showed faster surgical recovery than that of subgroup 1b (all P < 0.05). There was no difference in 5-year overall survival between groups 1 and 2 [87.1% (95% CI, 80.7-91.5%) vs. 87.1% (95% CI, 80.8-91.4%), P = 0.7420]. CONCLUSIONS: The FTMDT model, which integrates laparoscopic surgery, fast-track treatment, and XELOX chemotherapy, was the superior model for enhancing the recovery of Chinese patients with colorectal cancer. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01080547 , registered on March 4, 2010.

Effect of Dialysis on Antiplatelet Drug Efficacy in Uremic Patients with Coronary Heart Disease.

BACKGROUND: Coronary intervention therapy is the main treatment for uremic patients with coronary heart disease. The studies on whether dialysis reduces the efficacy of dual antiplatelet drugs are limited. The aim of this study was to examine the effect of dialysis on antiplatelet drugs in uremic patients with coronary heart disease. METHODS: This study included 26 uremic patients who had undergone percutaneous coronary intervention in China-Japan Friendship Hospital from November 2015 to May 2017. We examined their thromboelastography results before and after hemodialysis. Self-paired t-tests were employed to analyze changes in the inhibition rate of platelet aggregation. RESULTS: The mean inhibition rates of arachidonic acid-induced platelet aggregation before and after hemodialysis were 82.56 ± 2.79% and 86.42 ± 3.32%, respectively (t= -1.278, P= 0.213). The mean inhibition rates of adenosine diphosphate-induced platelet aggregation before and after hemodialysis were 67.87 ± 5.10% and 61.94 ± 5.90%, respectively (t = 1.425, P= 0.167). There was no significant difference in the inhibition rates of platelet aggregation before or after hemodialysis. These results also applied to patients with different sensitivity to aspirin and clopidogrel. CONCLUSION: Dialysis did not affect the antiplatelet effects of aspirin and clopidogrel in uremic patients with coronary heart disease.

A rapid amplification/detection assay for analysis of Mycobacterium tuberculosis using an isothermal and silicon bio-photonic sensor complex.

Global tuberculosis (TB) control is hampered by cost and slow or insensitive diagnostic methods to be used for TB diagnosis in clinic. Thus, TB still remains a major global health problem. The failure to rapidly and accurately diagnose of TB has posed significant challenges with consequent secondary resistance and ongoing transmission. We developed a rapid Mycobacterium tuberculosis (MTB) amplification/detection method, called MTB isothermal solid-phase amplification/detection (MTB-ISAD), that couples isothermal solid-phase amplification and a silicon biophotonics-based detection sensor to allow the simultaneous amplification and detection of MTB in a label-free and real-time manner. We validated the clinical utility of the MTB-ISAD assay by detecting MTB nucleic acid in sputum samples from 42 patients. We showed the ability of the MTB-ISAD assay to detect MTB in 42 clinical specimens, confirming that the MTB-ISAD assay is fast (<20 min), highly sensitive, accurate (>90%, 38/42), and cost-effective because it is a label-free method and does not involve thermal cycling. The MTB-ISAD assay has improved time-efficiency, affordability, and sensitivity compared with many existing methods. Therefore, it is potentially adaptable for better diagnosis across various clinical applications.

Oridonin in combination with celecoxib inhibits the proliferation and apoptosis of human osteosarcoma MG-63 cells in vitro / 肿瘤

Objective: To investigate the effects of diterpenoid oridonin combined with cyclooxygenase-2 (Cox-2) inhibitor celecoxib on proliferation and apoptosis of human osteosarcoma MG-63 cells, and to explore its possible mechanism. Methods: The inhibitory rates of proliferation of MG-63 cells after treatment with different concentrations of oridonin (20, 40 and 60 μmol/L) and celecoxib (25, 50 and 100 μmol/L) alone or in combination for different time periods were detected by MTT assay. The apoptosis rates of MG-63 cells after treatment with oridonin (40 μmol/L) and celecoxib (50 μmol/L) alone or in combination were detected by flow cytometry. The expression levels of Cox-2 and apoptosis regulatory factors B cell lymphoma-2 (Bcl-2), survivin and Bcl-2-associated X protein (Bax) mRNAs and proteins were detected by real-time fluorescence-based quantitative-PCR and Western blotting, respectively. Results: The proliferation inhibition rates of MG-63 cells in single drug groups (oridonin or celecoxib) and the combination group (oridonin and celecoxib) were increased as compared with that in the control group (without any treatment) (P < 0.05) in a dose-dependent manner. Oridonin and celecoxib had a synergistic effect at a low or moderate dose. The apoptosis rate of MG-63 cells after treatment with combination of oridonin and celecoxib was higher than those of the control group (without any treatment) and the single drug groups (P < 0.05). The expression levels of Cox-2, Bcl-2 and survivin mRNAs and proteins in combination group were significantly down-regulated as compared with those in the control group (without any treatment) and the single drug groups (all P < 0.05), whereas the expressions of Bax mRNA and protein were up-regulated (all P < 0.05). Conclusion: Oridonin in combination with celecoxib can synergistically inhibit the proliferation of MG-63 cells. This mechanism may be associated with the inhibition of expressions of Cox-2 and apoptosis regulatory factors.